Study details
Enrolling now
Ublituximab (Briumvi) Trial
Northwestern University
NCT IDNCT07225361ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
40
Study length
about 3.7 years
Ages
18–70
Locations
1 site in IL
What this study is about
This trial is testing a treatment called Ublituximab in people with early forms of relapsing multiple sclerosis. The goal is to see if this treatment is safe and tolerable, as well as how it affects plasma neurofilament light chain levels over time.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ublituximab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
ublituximab
Body systems
Neurology